Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NMRA
NMRA logo

NMRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Neumora Therapeutics Inc (NMRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.780
1 Day change
11.25%
52 Week Range
3.650
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

NMRA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The pre-market bounce is modest, but the broader technical trend is still bearish and there is no recent news or earnings data to support a long-term entry. Since the user wants a direct answer and is unwilling to wait for optimal entry points, my clear view is to avoid buying now and hold off.

Technical Analysis

NMRA is trading at 1.79 pre-market, up 2.29%, with the market still in pre-market and the S&P 500 down 0.36%. Technically, the stock is weak: SMA_200 > SMA_20 > SMA_5 indicates a bearish moving-average structure. RSI_6 at 34.661 is near oversold but not a strong reversal signal. The MACD histogram is slightly positive at 0.00711 but is contracting, which suggests momentum is not strongly improving. Key levels show pivot at 1.82, resistance at 1.942 and 2.017, while support sits at 1.697 and 1.622. The provided trend model also points lower over multiple horizons, with a 60% chance of -0.88% next day, -3.18% next week, and -4.78% next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mixed but not strongly bearish. The open interest put-call ratio of 0.25 suggests call interest is much higher than put interest, which is bullish on positioning. The option volume put-call ratio of 0.9 is closer to neutral, showing balanced near-term activity. However, total options activity is light relative to average, and implied volatility is very high at 279.77, with an IV percentile of 85.32, indicating expensive options and elevated uncertainty. This does not create a clean, low-risk long-term buy signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • Hedge funds are buying aggressively, with buying amount up 327.95% over the last quarter. Options positioning is skewed toward calls on open interest. Pre-market price is positive, which may reflect some short-term accumulation.

Neutral/Negative Catalysts

  • No news in the recent week means there is no event-driven catalyst or fresh fundamental driver. The technical trend remains bearish. Insiders are neutral. The stock trend model points to negative returns over the next day, week, and month. There is no recent congress trading data, and no strong AI Stock Pick or SwingMax signal today.

Financial Performance

No usable financial snapshot was provided because of an error, so there is no latest-quarter revenue, earnings, or growth data to support a long-term purchase decision. The missing financials weaken the case for a beginner long-term investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade cycle to support a buy thesis. Based on the information available, Wall Street pros would likely see the main positives as hedge fund accumulation and call-heavy options positioning, while the cons are the bearish chart, lack of news/catalyst, missing financial visibility, and weak near-term trend model.

Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
Wall Street analysts forecast NMRA stock price to rise
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 1.780
sliders
Low
3
Averages
9.33
High
18
Current: 1.780
sliders
Low
3
Averages
9.33
High
18
William Blair
Myles Minter
Market Perform
to
Outperform
upgrade
$7.62
AI Analysis
2026-02-17
Reason
William Blair
Myles Minter
Price Target
$7.62
AI Analysis
2026-02-17
upgrade
Market Perform
to
Outperform
Reason
William Blair analyst Myles Minter upgraded Neumora Therapeutics to Outperform from Market Perform with a net present value estimate of $7.62 per share. The firm increased its probability of success for NMRA-511 in Alzheimer's disease agitation to 35% after Neumora presented data from its Phase Ib study. The study showed meaningful reductions in the Cohen-Mansfield Agitation Inventory endpoint, the analyst tells investors in a research note. Blair continues to view Alzheimer's disease agitation as a blockbuster market opportunity with peak U.S. NMRA-511 sales of $1.8B "using conservative assumptions."
Mizuho
Outperform
maintain
$5 -> $6
2026-01-06
Reason
Mizuho
Price Target
$5 -> $6
2026-01-06
maintain
Outperform
Reason
Mizuho raised the firm's price target on Neumora Therapeutics to $6 from $5 and keeps an Outperform rating on the shares after the company made several announcements, highlighted by positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer's disease agitation. Better results seen in a pre-specified subset of AD patients with elevated anxiety is "an encouraging finding," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NMRA
Unlock Now

People Also Watch